|Dr. Timothy Charles Oldham B.Sc., BSc(Hons), L.L.B., LLB(Hons), Ph.D.||CEO, MD & Director||396.71k||N/A||N/A|
|Mr. Cameron Jones C.A.||Company Sec.||N/A||N/A||N/A|
AdAlta Limited, a clinical stage biotechnology company, discovers and develops protein therapeutics in Australia. The company's lead i-body drug candidate includes AD-214, which is in Phase I clinical trials for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has collaborative partnerships with GE Healthcare to discover i-bodies that bind to granzyme B; and Carina Biotech Pty Ltd. to develop CAR-T cell products against various solid tumor antigens. AdAlta Limited was incorporated in 2006 and is headquartered in Bundoora, Australia.
AdAlta Limited’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.